NAVISTAR INTERNATIONAL CORP Form 4 December 16, 2011 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **KAPUR DEEPAK TIGGHS** Issuer Symbol NAVISTAR INTERNATIONAL (Check all applicable) CORP [NAV] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner ___X__ Other (specify Officer (give title (Month/Day/Year) below) below) 4201 WINFIELD ROAD 12/15/2011 President, Truck Group Subsid (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting WARRENVILLE, IL 60555 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 6. Ownership 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of (D) Securities Form: Direct Indirect (Instr. 3) any Code (Instr. 3, 4 and 5) Beneficially (D) or Beneficial (Month/Day/Year) Owned Indirect (I) Ownership (Instr. 8) Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Common \$ 12/15/2011 F 661 D 64,317 D Stock 36.98 Premium 5.879 D

Share Units (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

0.5

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deri Secu Bene Own Follo Repo Tran (Inst
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
KAPUR DEEPAK TIGGHS 4201 WINFIELD ROAD WARRENVILLE, IL 60555				President, Truck Group Subsid			
Signatures							
Curt A. Kramer, Attorney in fact	12/	/16/2011					
**Signature of Reporting Person		Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Premium Share Units were acquired under Navistar's Executive Stock Ownership Program. Each Premium Share Unit represents one share of Navistar Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. t solid; padding-right: 6pt; padding-left: 6pt">

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

8.5% (2)

14

TYPE OF REPORTING PERSON

CO

Reporting Owners

Footnotes:

⁽¹⁾Shares of common stock are held of record by S.R. One, Limited (<u>"S.R. On</u>e"), an indirect, wholly-owned subsidiary of the Reporting Person.

(2) The calculation is based on a total of 23,313,250 shares of common stock outstanding as of March 12, 2015.

CUSIP No. 372427 10 4 SCHEDULE 13D/A1 Page 3 of 7

ITEM 1. SECURITY AND ISSUER

This Amendment No. 1 (the <u>"Amendment</u>") amends and supplements the Schedule 13D originally filed on February 14, 2014 (the <u>"Original Schedule 13D</u>") with respect to the shares of common stock, par value \$0.001 per share (<u>"Shares</u>"), of Genocea Biosciences, Inc., a Delaware corporation (the <u>"Issuer</u>"). The Issuer's principal executive offices are located at 100 Acorn Park Drive, Cambridge, Massachusetts 02140. This Amendment No. 1 is being filed to disclose changes to beneficial ownership as a result of the allocation of Shares to the Reporting Persons. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.

ITEM 2. IDENTITY AND BACKGROUND

This Amendment amends and restates Item 2 of the Original Schedule 13D by deleting Schedule 1 in its entirety, and replacing it with Schedule 1 attached hereto.

ITEM 4. PURPOSE OF TRANSACTION

The response set forth in Item 4 (A) of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

Effective December 12, 2014, Dr. Simeon J. George voluntarily retired from the Board of Directors of the Issuer (the <u>"Board</u>"). Dr. George has served on the Board since 2009 and has also served as a member of the Audit Committee and Compensation Committee. Dr. George's retirement was in accordance with the investment policies of S.R. One.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The response set forth in Items 5 (A) and (B) of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

On March 12, 2015, S.R. One was allocated 300,000 Shares at a price of \$8.25 per Share. As a result, a. GlaxoSmithKline plc beneficially owns 1,971,668 Shares which represents 8.5% of the 23,313,250 Shares outstanding as of March 12, 2015.

b. GlaxoSmithKline plc has the sole power to vote or direct the vote, and the sole power to dispose or to direct the disposition of, all 1,971,668 Shares described in Item 5a above.

CUSIP No. 372427 10 4 SCHEDULE 13D/A1 Page 4 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 16, 2015

GLAXOSMITHKLINE PLC

By: /s/ Victoria A. Whyte

Name: Victoria A. Whyte Title: Company Secretary

CUSIP No. 372427 10 4 SCHEDULE 13D/A1 Page 5 of 7

Schedule I

Name Board of Directors	Business Address	Principal Occupation or Employment	Citizenship		
Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Executive Officer British			
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS 709 Swedeland Road	Executive Director and Chief Financial Officer British			
Dr. Moncef Slaoui	King of Prussia Pennsylvania	Executive Director and Chairman Global Vaccines	Moroccan, Belgian & US		
Sir Christopher Gent	19406 980 Great West Road Brentford Middlesex, England TW8 9GS	Chairman and Company Director	British		
Sir Philip Hampton	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British		
Professor Sir Roy Anderson	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British		
Dr. Stephanie Burns	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US		
Stacey Cartwright	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British		
Judy Lewent	980 Great West Road Brentford Middlesex, England	Company Director	US		
Sir Deryck Maughan	TW8 9GS	Company Director	British		

Explanation of Responses:

980 Great West Road Brentford Middlesex, England TW8 9GS

CUSIP No. 372427 10 4 SCHEDULE 13D/A1 Page 6 of 7

Dr. Daniel Podolsky	TW8 9GS	Company	Director US	
Tom de Swaan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company	Director Dutch	
Lynn Elsenhans	980 Great West Road Brentford Middlesex, England TW8 9GS 980 Great West Road	Company	Director US	
Jing Ulrich	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company	Director US	
Hans Wijers	Brentford Middlesex, England TW8 9GS		Director Dutch	
Urs Rohner	980 Great West Road Brentford Middlesex, England TW8 9GS		Director Swiss	
Corporate Executiv	ve Team			
Sir Andrew Witty Sir Andrew Witty Middlesex, H TW8 9GS		England	Executive Director and Chief Executive Officer	British
Simon Dingemans Simon Dingemans TW8 9GS 709 Swedela		England	Executive Director and Chief Financial Officer British	
Dr. Moncef Slaoui	King of Prus Pennsylvani		Executive Director Chairman Global Vaccines	Moroccan, Belgian & US
	10406			

CUSIP No. 372427 10 4 SCHEDULE 13D/A1 Page 7 of 7

	980 Great West Road		British
Nick Hirons	Brentford	Senior Vice President, Global Ethics and Compliance	
	Middlesex		
	TW8 9GS		
		President, Global Pharmaceuticals	
Abbas Hussain	150 Beach Road 22-00 Gateway West 189720		British
William Louv	Singapore Five Moore Drive PO Box 13398 Research Triangle Park North Carolina 27709 980 Great West Road	Senior Vice President, Core Business Services	US
David Redfern	Brentford Middlesex, England TW8 9GS	Chief Strategy Officer	British
Claire Thomas	980 Great West Road Brentford Middlesex, England TW8 9GS	Senior Vice President, Human Resources	British
Philip Thomson	980 Great West Road Brentford Middlesex, England TW8 9GS	Senior Vice President, Communications and Government Affair	s British
Daniel Troy	5 Crescent Drive Philadelphia, PA 19112	Senior Vice President & General Counsel	US
Dr. Patrick Vallanc	Middlesex, England TW8 9GS	President, Pharmaceuticals R&D	British
Emma Walmsley	980 Great West Road Brentford Middlesex, England TW8 9GS	President, Consumer Healthcare	British
Roger Connor	980 Great West Road Brentford Middlesex, England TW8 9GS	President, Global Manufacturing & Supply	Irish